High Court victory for glucosamine users

Natural Health News – The drama that may have gone by and yet if taken as glucosamine supplement is directly relevant to you.

In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) classifies glucosamine and related glucosamine supplements. They are widely available over the counter and in a variety of doses and formulations.

But in 2013 a large pharmaceutical company, the European arm of the Chinese company BlueBio (Yantai) Pharmaceutical products, mount a challenge in the Supreme Court of glucosamine have reclassified as a medicine.

Indeed, although there have been several previous to the position of the MHRA that glucosamine is not a drug challenges, this challenge was seen by many as the most determined yet.

Using the mechanism of judicial review in the Supreme Court, BlueBio sought a declaration from the Court that all products containing glucosamine should be reclassified as medicinal – and only for relieving osteo-arthiritis of knee, or failing a statement that all those products marketed with a recommended daily dose of 1500 mg are medicinal products.

Joining forces

The movement saw the MHRA and Health Food Manufacturers’ Association of the United Kingdom (AMF) – groups they are not always agree – joining forces to crush the challenge


CEO AMF Graham Keen at the time that there would be “serious and far-reaching consequences” if the challenge were successful and the AMF he presented a substantial contribution to the Court in support of the position of the MHRA presentation.

Keen also warned “not only the market for large glucosamine value food trade health food would be lost, also have immediate implications for the future state of food supplements other substances, particularly those that have licensed equivalent -. eg oil cod liver, folic acid and vitamins D and B12 a worrying precedent could also be established by which the capacity of the MHRA to review products on a case-by-case basis is seriously threatened. ”

“This is a decisive time for our industry. We can not afford to be one of those times when we look back in five years and say” how on earth do we allow this to happen ‘. “

a victory for common sense

last week judicial review concluded that glucosamine could remain on the market. the statement said among other things the predominant use of glucosamine and related products is as a nutritional supplement. it was also noted, in essence, that just because a substance has a medicinal action, that does not automatically make it a drug.

Speaking about the if Keen said:

“we are very pleased with the outcome of this very significant event, which had a very real ability to have a profound impact on the future for our members, the industry and, perhaps most importantly, consumer choice.

“We are relieved that the judge has rejected so clearly all the claims made by the plaintiff in this case, and so quickly. We have argued vigorously throughout the case that the current state of food supplement for glucosamine should be maintained, and the Honourable Mr. Justice Supperstone agrees with this clarity, citing much of our argument in its judgment.

“we are delighted to have played a supporting role as key to helping the MHRA to defend this action and thank, in particular, let our excellent lawyer, Brian Kelly, Covington & Burling, which represented us in the audience, and those companies, both members and non-members of the AMF, whose financial support has enabled us to intervene in this case. “

It is still unknown whether Blue Bio mount an additional challenge to the judgment.

Add a Comment

==[Click 2x to Close X]==
Most Popular Today!

Sorry. No data so far.